Long-term effects of lifestyle and metformin interventions in DPP on bone density

Publication Description
In the Diabetes Prevention Program Outcome Study (DPPOS), a cohort at high risk of diabetes, randomization to intensive lifestyle intervention or metformin, both associated with weight loss, did not have long-term negative effects on BMD compared with the placebo group. Potential positive effects of metformin on bone warrant further investigation. INTRODUCTION: Randomization to lifestyle intervention (ILS) or metformin in the Diabetes Prevention Program (DPP) resulted in weight loss and reduced progression to diabetes. Weight loss is associated with reduced bone mineral density (BMD), but the long-term effects of these interventions on BMD are unknown. In the DPP Outcome Study (DPPOS), we determined if randomization to ILS or metformin, compared with placebo, was associated with differences in BMD approximately 16 years later. METHODS: Of 3234 DPP participants, 2779 continued in DPPOS and were offered ILS in group format. Those randomized to metformin were offered unmasked metformin. At DPPOS year 12, 1367 participants had dual-energy X-ray absorptiometry scans. BMD in metformin and ILS groups was compared to placebo using sex-specific linear regression models, adjusted for age, race/ethnicity, and weight and weight-bearing activity at DPP baseline. RESULTS: At DPPOS year 12, mean age was 66.5 (+/-9.5) years. Femoral neck BMD was similar in the ILS and placebo groups in men (difference = -0.021 g/cm(2), 95%CI (-0.063, 0.021)) and in women (+0.014 g/cm(2), 95%CI (-0.014, 0.042)). Femoral neck BMD was higher in the metformin compared to placebo group although not statistically different in men (+0.017 g/cm(2), 95% CI (-0.023, 0.058)) and in women (+0.019 g/cm(2), 95% CI (-0.009, 0.047)). Prevalence of osteoporosis was low and similar across treatment groups in men (0.9%; p=0.745) and women (2.4%; p=0.466). CONCLUSION: In a cohort at high risk of diabetes, lifestyle intervention or metformin did not appear to have long-term negative effects on BMD. Potential positive effects of metformin on bone warrant further research.

Primary Author
Schwartz,A. V.
Pan,Q.
Aroda,V. R.
Crandall,J. P.
Kriska,A.
Piromalli,C.
Wallia,A.
Temprosa,M.
Florez,H.
Diabetes Prevention Program Research Group

Author Address
Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA, USA. [email protected].; Department of Statistics and The Biostatistics Center, George Washington University, Washington, D.C., USA.; Me(TRUNCATED)

Author Address
Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA, USA. [email protected].; Department of Statistics and The Biostatistics Center, George Washington University, Washington, D.C., USA.; Me(TRUNCATED)

PMID
34086101



Reference Type
Journal Article

Periodical Full
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA

Publication Year
2021

Publication Date
4-Jun

Place of Publication
England

ISSN/ISBN
1433-2965

Document Object Index
10.1007/s00198-021-05989-1 [doi]

Accession Number
PMID: 34086101